Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Blinatumomab Represents a New Standard of Care in Pediatric High-Risk First-Relapse ALL

September 2nd 2020

Blinatumomab monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant resulted a significant improvement in event-free survival and a lower risk of recurrence in children with high-risk B-cell precursor–acute lymphoblastic leukemia.

Belumosudil Continues to Elicit Statistically Significant Responses in cGVHD

September 2nd 2020

The orally available ROCK2 selective inhibitor belumosudil continues to elicit clinically meaningful overall response rates in patients with chronic graft-versus-host disease (cGVHD) who have received ≥2 prior lines of systemic therapy

Subcutaneous Daratumumab in Myeloma Does Not Require Dose Individualization Based on Body Weight

September 1st 2020

The overall response rates with subcutaneous daratumumab proved to be similar to that of the intravenous formulation of the drug irrespective of body weight.

FDA Approves Oral Azacitidine for Acute Myeloid Leukemia

September 1st 2020

The FDA has approved oral azacitidine for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy who are not able to complete intensive curative therapy.

FDA Grants Priority Review to Oral Paclitaxel/Encequidar for Metastatic Breast Cancer

September 1st 2020

The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer.

FDA Grants Priority Review to Melphalan Flufenamide for Triple-Class Refractory Myeloma

August 31st 2020

The FDA has granted a priority review to a new drug application for melphalan flufenamide for use in combination with dexamethasone in adult patients with multiple myeloma whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody.

Belantamab Mafodotin Approved in Europe for Relapsed/Refractory Multiple Myeloma

August 27th 2020

The European Commission has approved belantamab mafodotin-blmf for the treatment of adult patients with multiple myeloma who have received at least 4 previous therapies, whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-CD38 monoclonal antibody, and who have progressed on their last therapy.

FDA Approves FoundationOne Liquid CDx for Solid Tumors

August 27th 2020

The FDA has approved the FoundationOne Liquid CDx, a liquid biopsy for all solid tumors with multiple companion diagnostic indications.

ERC1671 Immunotherapy Shows Early Promise in Recurrent Glioblastoma

August 26th 2020

The investigational immunotherapeutic ERC1671 in combination with granulocyte-macrophage colony-stimulating factor, cyclophosphamide, and bevacizumab showed promising activity in patients with recurrent glioblastoma.

Ilixadencel Plus Sunitinib Shows Survival Benefit in Metastatic RCC

August 26th 2020

The combination of the off-the-shelf cancer immune primer Ilixadencel and sunitinib has demonstrated promising survival benefit when used as a frontline treatment for newly diagnosed patients with metastatic renal cell carcinoma.

Asciminib Elicits Significant Major Molecular Responses in Ph+ Chronic-Phase CML

August 26th 2020

The novel investigational STAMP inhibitor asciminib significantly improved the major molecular response rate compared with bosutinib at 24 weeks in adult patients with Philadelphia chromosome–positive, chronic-phase chronic myeloid leukemia who received prior treatment with 2 or more TKIs.

FDA Approves Generic Pemetrexed for Nonsquamous NSCLC

August 25th 2020

The FDA has approved a generic form of pemetrexed for intravenous administration as a single-agent in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer that has not progressed following 4 cycles of first-line platinum-based chemotherapy.

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

August 25th 2020

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Enasidenib Plus Best Supportive Care Misses OS End Point in Relapsed/Refractory IDH2+ AML

August 25th 2020

Enasidenib in combination with best supportive care failed to significantly improve overall survival in patients with relapsed/refractory acute myeloid leukemia whose tumors harbor an IDH2 mutation.

Tesetaxel Plus Reduced-Dose Capecitabine Significantly Prolongs PFS in Metastatic Breast Cancer

August 24th 2020

Tesetaxel in combination with a reduced dose of capecitabine led to a significant improvement in progression-free survival versus the approved dose of capecitabine alone, meeting the primary end point of the phase 3 CONTESSA trial.

Pembrolizumab Receives 2 New Approvals Across Oncology in Japan

August 24th 2020

The Japan Pharmaceuticals and Medical Devices Agency has approved pembrolizumab for the treatment of patients with radically unresectable, advanced, or recurrent esophageal squamous cell carcinoma whose tumors are PD-L1–positive, and at an additional recommended dosage of 400 mg every 6 weeks as an intravenous infusion across all adult indications.

Rigosertib Fails to Meet OS End Point in Higher-Risk MDS

August 24th 2020

Intravenous rigosertib did not meet the primary end point of significantly improved overall survival versus physician’s choice of therapy plus best supportive care in patients with higher-risk myelodysplastic syndromes.

Spartalizumab Plus Dabrafenib/Trametinib Misses PFS End Point in BRAF V600+ Melanoma

August 24th 2020

Spartalizumab in combination with dabrafenib and trametinib failed to meet the primary end point of investigator-assessed progression-free survival in treatment-naïve patients with unresectable or metastatic BRAF V600 mutation–positive cutaneous melanoma.

FDA Approves Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

August 20th 2020

The FDA has approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received 1 or more prior lines of therapy.

Bevacizumab Biosimilar Aybintio Approved in Europe

August 20th 2020

The European Commission has granted a marketing authorization to Aybintio, a bevacizumab biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.